Yiru Guo, MD, FAHA

Professor of Medicine, Pharmacology, Toxicology, Physiology and Biophysics
Division of Cardiovascular Medicine
Director, the Murine Research Laboratory
Leader, the NIH-funded Murine Surgery, Physiology and Transgenic Core
Institute of Molecular Cardiology, University of Louisville
511 S Floyd Street, MDR Building Room 128D
Louisville, KY 40202, USA

Biography

Dr. Guo is a Professor of Medicine/the Division of Cardiology at University of Louisville. He has been the Director of Murline Research Laboratory since 1997. He is also the Director of Surgery and Transgenic core in the NIH PPG. In 2007, he was elected as the Fellow of the national AHA(FAHA) because of his major and productive contributors to the cardiovascular basic science. His research has been supported by several NIH grants including R01, PPG and CAESAR grants. He has been co-authored over 60 peer-reviewed publications, several book chapters, and has been invited to speak at several international scientific meetings and research institutes/universities.

Research Interest

His research interests include: Elucidating the mechanisms of ischemic-pharmacologic and ischemia/reperfusion model in genetically engineered animals, Studying protection of ischemic myocardium by using gene and/or cell therapy, Elucidating adaptations to ischemia/reperfusion injury in the aging heart.

Scientific Activities

HONORS AND AWARDS

• (1998-1999) Postdoctoral Fellowship Award, American Heart Association, Kentucky Affiliate, USA
• (11/1998) Travel Award (American Heart Association, Cardiovascular Surgery and Anesthesia Council), Dallas, TX, USA
• (1999-2000) Postdoctoral Fellowship Award, American Heart Association, Ohio Valley Affiliate, USA
• (06/2000) Organizer of the XXII Annual Sessions of the American Section of the International Society for Heart Research (ISHR), Louisville, KY, USA (June 14-18, 2000)
• (05/2001) Honored and Visiting Professor in the Institute of Cardiovascular Diseases of Capital University of Medical Science, the Heart Center of Beijing Chao Yang Hospital, Beijing, China
• (11/2001) Second Place Award in Scientific Importance category in ResearchLouisville Competition, Louisville, KY, USA
• (11/2001) Honored Member in Good Standing (the International Society for Heart Research-American Section)
• (07/2002) Nominated as International Scientist of the Year from the International Biographical Centre of Cambridge (IBC)
• (11/2003) Travel Award (American Heart Association, Council on Basic Cardiovascular Sciences), Dallas, TX, USA
• (11/2007) Fellow of the American Heart Association (Council on Basic Cardiovascular Sciences), USA
• (08/14/2011) Chairing Section entitled Cell Transplantation and Cardiac Regeneration: From Bench to Bedside. China Heart Congress (CHC) and International Heart Forum Beijing (IHF), China

PROFESSIONAL MEMBERSHIPS AND ACTIVITIES

• (1986-1996) Member of Chinese Cardiothoracic and Vascular Surgery Society
• (1990-1996) Member of Chinese Biomedical Engineering Society
• (1996-present) Member of the American Heart Association (Council on Cardio-Thoracic and Vascular Surgery)
• (1997-present) Member of the Oxygen Society of USA
• (1997-present) Member of the International Society for Heart Research (ISHR)-American Section
• (1999-present) Member of the American Association for the Advancement of Science (AAAS)
• (2000) One of organizers of the XXII Annual Sessions of the American Section of the International Society for Heart Research (ISHR), Louisville, KY, June 14-18, 2000
• (2001-present) Member of the American Heart Association (Council on Basic Cardiovascular Sciences)
• (2004-present) Member of Interdisciplinary Research Group on Aging in Louisville
• (2004-2006) Professional Member of the American Heart Association (Councils on Basic Cardiovascular Sciences and Cardiothoracic and Vascular Surgery)
• (2006-present) Premium Professional Member of the American Heart Association (Councils on Basic Cardiovascular Sciences, Cardiothoracic and Vascular Surgery and Interdisciplinary Working Group on Atherosclerotic Peripheral Vascular Disease)
• (2007-present) Fellow of the American Heart Association (FAHA, Councils on Basic Cardiovascular Sciences)
• (2010-present) Member of NIH CAESAR Consortium Operations Committee (COC), USA
• (2011-present) Member of International Steering Committee, China Heart Congress and International Heart Forum, Beijing, China

Publications

Original Research Articles

1. Guo JH, Guo JQ, Guo Y, Wu XJ. Calculation of the diameter of pulmonary arterial orifile and transannular patch width in radical treatment of tetralogy of Fallot. Chinese Circulation. 1992; 7: 196-199. doi:
2. Wu XJ, Qi ZT, Guo Y, Guo JQ. Effect of cryopreservation on the mechanical behavior thoracic aortic allografts. Chinese J. Dial and Artif Organs. 1992; 3: 4-6.
3. Chang Q, Guo JQ, Guo Y, Wu XJ. In vitro hydrolic simulation of Fontan circulation and flow visualization and hemodynamic study. Proceedings of 1st ICBME Shanghai 5th ISBMRE. 1992; 1: 236-237.
4. Chang Q, Guo JQ, Guo Y, Wu XJ. Hemodynamic appreciation of Fontan procedure using the method of mathematical analysis of pulse wave. Proceedings of 1st ICBME Shanghai 5th ISBMRE. 1992; 1: 103-110.
5. Wu XJ, Guo JQ, Guo Y, Chang Q. Clinical basis for the research and practice of human circulation duplicator attaching with clinical information including left heart cathertization of 74 cases. Proceedings of 1st ICBME 92 Shanghai 5th ISBMRE. 1992; 1: 203-210.
6. Wu XJ, Guo JQ, Guo Y, Chang Q. The influence of left ventricular morphology size and motion on hydrodynamic character of left human circulation-background knowledge of human circulation duplication from clinical observation. J Biomed Eng. 1992; 9: 353-358.
7. Wu XJ, Chang Q, Guo Y, Guo JQ. Study of aortic valve allograft as standard comparative valve in hydrodynamic characteristic testing heart valve prosthesis mounted with trestle tested in pulse flow. J Biomed Eng. 1993; 10(1): 27-35.
8. Wu XJ, Chang Q, Guo Y, Guo JQ. Comparison of allograft aortic valve orifice area as estimated by the gorlin formula and the continuity equation. ACTA Academia Medicine Science. 1993; 15: 411-416.
9. Guo Y, Guo JQ. Directing gene transfer into rat myocardium in vivo. J Beijing Med Univ. 1994; 26: 128-130.
10. Chen LW, Guo Y, Guo JQ. A tentative application of pro-urokinase gene suture for vascular anastomosis. J Beijing Med Univ. 1994; 26: 134.
11. Zhu XD, Liu YL, Xiao MD, Guo Y. Correction of complex congenital hearts anomalies with Rastelli operation. International Conference on Extracorporeal Circulation and Thoracic & Cardiovascular Surgery. Beijing. 1994; 10: 136-137.
12. Wu XJ, Guo JH, Guo Y, Guo JQ. Evaluation and similarity of the duplicators cardiac cycle in vivo. J Beijing Biomed Eng. 1994; 13: 91-92.
13. Bolli R, Bhatti ZA, Tang XL, Qiu Y, Guo Y, Jadoon AK. Evidence that late preconditioning against myocardial stunning in conscious rabbits is triggered by the generation of nitric oxide. Circ Res. 1997; 81(1): 42-52.
14. Bolli R, Manchikalapudi S, Tang XL, et al. The protective effect of late preconditioning against myocardial stunning in conscious rabbits are mediated by nitric oxide synthase evidence that nitric oxide acts both as a trigger and as a mediator of the late phase of ischemic preconditioning. Circ Res. 1997; 81(6): 1094-1107.
15. Takano H, Tang XL, Qiu Y, Guo Y, French BA, Bolli R. Nitric oxide donors induce late preconditioning against myocardial stunning and infarction in conscious rabbits via an antioxidant-sensitive mechanism. Circ Res. 1998; 83(1): 73-84.
16. Guo Y, Wu WJ, Qiu Y, Tang XL, Yang Z, Bolli R. Demonstration of an early and a late phase of ischemic preconditioning in mice. Am J Physiol. 1998; 275(4(2)): H1375-H1387.
17. Yuan SM, Chang Q, Guo Y and Guo JQ. In vitro pulsatile flow visualization on extracardiac conduits for the right ventricular outflow tract reconstruction qualitative considerations. Kaohsiung J Med Sci. 1998; 14(5): 258-265.
18. Guo Y, Jones WK, Xuan Y, et al. The late phase of ischemic preconditioning is abrogated by targeted disruption of the inducible NO synthase gene. Proc Natl Acad Sci USA. 1999; 96(20): 11507-11512.
19. Guo Y, Bao W, Wu JW, Shinmura K, Tang XL, Bolli R. Evidence for an essential role of cyclooxygenase-2 as a mediator of the late phase of ischemic preconditioning in mice. Basic Res Cardiol. 2000; 95(6): 479-484.
20. Guo Y, Bolli R, Bao W, et al. Targeted deletion of the A3 adenosine receptor confers resistance to myocardial ischemic injury and does not prevent early preconditioning. J Mol Cell Cardiol. 2001; 33(4): 825-830.
21. Li Q, Bolli R, Qiu Y, Tang XL, Guo Y, French BA. Gene therapy with extracellular superoxide dismutase protects conscious rabbits against myocardial infarction. Circulation. 2001; 10(103(14)): 1893-1898.
22. Xuan YT, Guo Y, Han H, Zhu Y, Bolli R. An essential role of the JAK-STAT pathway in ischemic preconditioning. Proc Natl Acad Sci USA. 2001; 98(16): 9050-9055.
23. Chen L, Hahn H, Wu G, et al. Opposing cardioprotective actions and parallel hypertrophic effects of delta PKC and epsilon PKC. Proc Natl Acad Sci USA. 2001; 98(20): 11114-11119. 24. Ping P, Song C, Zhang J, et al. Formation of protein kinase C(epsilon)-Lck signaling modules confers cardioprotection. J Clin Invest. 2002; 109(4): 499-507.
25. Wang Y, Guo Y, Zhang SX, et al. Ischemic preconditioning upregulates inducible nitric oxide synthase in cardiac myocyte. J Mol Cell Cardiol. 2002; 34(1): 5-15.
26. Black RG Jr, Guo Y, Ge ZD, et al. Gene dosage-dependent effects of cardiac-specific overexpression of the A3 adenosine receptor. Circ Res. 2002; 91(2): 165-172.
27. Sasaki N, Murata M, Guo Y, et al. Mcc-134, a single pharmacophore, opens surface ATP-sensitive potassium channels, blocks mitochondrial ATP-sensitive potassium channels, and suppresses preconditioning. Circulation. 2003; 107(8): 1183-1188.
28. Li Q, Guo Y, Xuan YT, et al. Gene Therapy with Inducible Nitric Oxide Synthase Protects against Myocardial Infarction via a Cyclooxygenase-2-dependent Mechanism. Circ Res. 2003; 92(7): 741-748.
29. Baines CP, Song CX, Zheng YT, et al. Protein Kinase C epsilon Interacts With and Inhibits the Permeability Transition Pore in Cardiac Mitochondria. Circ Res. 2003; 92(8): 873-880.
30. Xuan YT, Guo Y, Zhu Y, et al. Mechanism of cyclooxygenase-2 upregulation in late preconditioning. J Mol Cell Cardiol. 2003; 35(5): 525-537.
31. Guo Y, Stein AB, Wu WJ, et al. Administration of a CO-releasing molecule at the time of reperfusion reduces infarct size in vivo. Am J Physiol Heart Circ Physiol. 2004; 286(5): H1649-H1653.
32. Dawn B, Guo Y, Rezazadeh A, et al. Tumor necrosis factor-alpha does not modulate ischemia/reperfusion injury in naive myocardium but is essential for the development of late preconditioning. J Mol Cell Cardiol. 2004; 37(1): 51-61.
33. Dawn B, Xuan YT, Guo Y, et al. IL-6 plays an obligatory role in late preconditioning via JAK-STAT signaling and upregulation of iNOS and COX-2. Cardiovasc Res. 2004; 64(1): 61-71.
34. Kucia M, Dawn B, Hunt G, et al. Cells expressing early cardiac markers reside in the bone marrow and are mobilized into the peripheral blood after myocardial infarction. Circ Res. 2004; 95(12): 1191-1209.
35. Stein AB, Guo Y, Tan W, et al. Administration of a CO-releasing molecule induces late preconditioning against myocardial infarction. J Mol Cell Cardiol. 2005; 38(1): 127-134.
36. Martindale JJ, Wall JA, Martinez-Longoria DM, et al. Overexpression of Mitogen-activated Protein Kinase Kinase 6 in the Heart Improves Functional Recovery from Ischemia in Vitro and Protects against Myocardial Infarction in Vivo. J Biol Chem. 2005; 280(1): 669-676.
37. Syed FM, Hahn HS, Odley A, et al. Proapoptotic effects of caspase-1/interleukin-converting enzyme dominate in myocardial ischemia. Circ Res. 2005; 96(10): 1103-1109.
38. Guo Y, Stein AB, Wu WJ, et al. Late preconditioning induced by NO donors, adenosine A1 receptor agonists, and δ1-opioid receptor agonists is mediated by iNOS. Am J Physiol Heart Circ Physiol. 2005; 289(5): H2251-H2257.
39. Xuan YT, Guo Y, Zhu Y, et al. Role of the protein kinase C-epsilon-Raf-1-MEK-1/2-p44/42 MAPK signaling cascade in the activation of signal transducers and activators of transcription 1 and 3 and induction of cyclooxygenase-2 after ischemic preconditioning. Circulation. 2005; 112(13): 1971-1978.
40. Li Q, Guo Y, Tan W, et al. Gene therapy with iNOS provides long-term protection against myocardial infarction without adverse functional consequences. Am J Physiol Heart Circ Physiol. 2006; 290(2): H584-H589.
41. Dawn B, Guo Y, Rezazadeh A, et al. Postinfarct Cytokine Therapy Regenerates Cardiac Tissue and Improves Left Ventricular Function. Circ Res. 2006; 98(8): 1098-1105.
42. Stein AB, Bolli R, Guo Y, et al. The late phase of ischemic preconditioning induces a prosurvival genetic program that results in marked attenuation of apoptosis. J Mol Cell Cardiol. 2007; 42(6): 1075-1085.
43. Xuan YT, Guo Y, Zhu Y, Wang OL, Rokosh G, Bolli R. Endothelial Nitric Oxide Synthase Plays an Obligatory Role in the Late Phase of Ischemic Preconditioning by Activating the Protein Kinase C{epsilon}-p44/42 Mitogen-Activated Protein Kinase-pSer-Signal Transducers and Activators of Transcription1/3 Pathway. Circulation. 2007; 116(5): 535-544.
44. Hu X, Dai S, Wu WJ, et al. Stromal Cell-Derived Factor-1{alpha} Confers Protection Against Myocardial Ischemia/Reperfusion Injury. Role of the Cardiac Stromal Cell-Derived Factor-1{alpha}-CXCR4 Axis. Circulation. 2007; 116(6): 654-663.
45. Li Q, Guo Y, Tan W, et al. Cardioprotection Afforded by Inducible Nitric Oxide Synthase Gene Therapy Is Mediated by Cyclooxygenase-2 via a Nuclear Factor-{kappa}B Dependent Pathway. Circulation. 2007; 116(14): 1577-1584.
46. Benjamin IJ, Guo Y, Srinivasan S, et al. CRYAB and HSPB2 deficiency alters cardiac metabolism and paradoxically confers protection against myocardial ischemia in aging mice. Am J Physiol Heart Circ Physiol. 2007; 293(5): H3201-H3209.
47. Guo Y, Li Q, Wu W, et al. Endothelial nitric oxide synthase is not necessary for the early phase of ischemic preconditioning in the mouse. J Mol Cell Cardiol. 2008; 44(3): 496-501.
48. Dawn B, Tiwari S, Kucia MJ, et al. Transplantation of Bone Marrow-Derived Very Small Embryonic-like Stem Cells (Vsels) Attenuates Left Ventricular Dysfunction and Remodeling after Myocardial Infarction. Stem Cells. 2008. doi: 10.1634/stemcells.2007-0715.
49. Zuba-Surma EK, Kucia M, Dawn B, Guo Y, Ratajczak MZ, Bolli R. Bone marrow-derived pluripotent very small embryonic-like stem cells (VSELs) are mobilized after acute myocardial infarction. J Mol Cell Cardiol. 2008; 44(5): 865-873. doi: 10.1016/j.yjmcc.2008.02.279.
50. Wang GW, Guo Y, Vondriska TM, et al. Acrolein consumption exacerbates myocardial ischemic injury and blocks nitric oxide-induced PKCepsilon signaling and cardioprotection. J Mol Cell Cardiol. 2008; 44(6): 1016-1022. doi: 10.1016/j.yjmcc.2008.03.020.
51. Flaherty MP, Guo Y, Tiwari S, et al. The role of TNF-alpha receptors p55 and p75 in acute myocardial ischemia/reperfusion injury and late preconditioning. J Mol Cell Cardiol. 2008; 45(6): 735-741. doi: 10.1016/j.yjmcc.2008.08.014.
52. West MB, Rokosh G, Obal D, et al. Cardiac myocyte-specific expression of inducible nitric oxide synthase protects against ischemia/reperfusion injury by preventing mitochondrial permeability transition. Circulation. 2008; 118(19): 1970-1978. doi: 10.1161/CIRCULATIONAHA.108.791533.
53. Li Q, Guo Y, Ou Q, et al. Gene Transfer of Inducible Nitric Oxide Synthase Affords Cardioprotection by Upregulating Heme Oxygenase-1 Via a Nuclear Factor-{kappa}B-Dependent Pathway. Circulation. 2009; 120(13): 1222-1230. doi: 10.1161/CIRCULATIONAHA.108.778688.
54. Sanganalmath SK, Stein AB, Guo Y, et al. The beneficial effects of postinfarct cytokine combination therapy are sustained during long-term follow-up. J Mol Cell Cardiol. 2009; 47(4): 528-535. doi: 10.1016/j.yjmcc.2009.07.009.
55. Bolli R, Stein AB, Guo Y, et al. A murine model of inducible, cardiac-specific deletion of STAT3: its use to determine the role of STAT3 in the upregulation of cardioprotective proteins by ischemic preconditioning. J Mol Cell Cardiol. 2011; 50(4): 589-597. doi: 10.1016/j.yjmcc.2011.01.002.
56. Zuba-Surma EK, Guo Y, Taher H, et al. Transplantation of expanded bone marrow-derived very small embryonic-like stem cells (VSEL-SCs) improves left ventricular function and remodeling after myocardial infarction. J Cell Mol Med. 2011; 15(6): 1319-1328. doi: 10.1111/j.1582-4934.2010.01126.x.
57. Li Q, Guo Y, Ou Q, et al. Intracoronary administration of cardiac progenitor cells in mice: A new, improved technique for cell therapy in murine models. Basic Res Cardiol. 2011; 106(5): 849-864. doi: 10.1007/s00395-011-0180-1.
58. Li Q, Guo Y, Wu W, et al. Gene transfer as a strategy to achieve permanent cardioprotection I: rAAV-mediated gene therapy with inducible nitric oxide synthase limits infarct size 1 year later without adverse functional consequences. Basic Res Cardiol. 2011; 106(6): 1355-1366. doi: 10.1007/s00395-011-0207-7.
59. Li Q, Guo Y, Ou Q, et al. Gene transfer as a strategy to achieve permanent cardioprotection II: rAAV-mediated gene therapy with heme oxygenase-1 limits infarct size 1 year later without adverse functional consequences. Basic Res Cardiol. 2011; 106(6): 1367-1377. doi: 10.1007/s00395-011-0208-6.
60. Stein AB, Bolli R, Dawn B, et al. Carbon monoxide induces a late preconditioning-mimetic cardioprotective and antiapoptotic milieu in the myocardium. J Mol Cell Cardiol. 2012; 52(1): 228-236. doi: 10.1016/j.yjmcc.2011.11.005.
61. Guo Y, Sanganalmath SK, Wu W, et al. Identification of Inducible Nitric Oxide Synthase in Peripheral Blood Cells as a Mediator of Myocardial Ischemia/Reperfusion Injury. Basic Res Cardiol. 2012; 107(2): 253. doi: 10.1007/s00395-012-0253-9.
62. Guo Y, Tukaye DN, Wu WJ, et al. The COX-2/PGI2 receptor axis plays an obligatory role in mediating the cardioprotection conferred by the late phase of ischemic preconditioning. PLoS One. 2012; 7(7): e41178. doi: 10.1371/journal.pone.0041178.
63. Guo Y, Flaherty MP, Wu WJ, et al. Genetic background, gender, age, body temperature, and arterial blood pH have a major impact on myocardial infarct size in the mouse and need to be carefully measured and/or taken into account: results of a comprehensive analysis of determinants of infarct size in 1,074 mice. Basic Res Cardiol. 2012; 107(5): 288. doi: 10.1007/s00395-012-0288-y.
64. Cai C, Teng L, Vu D, et al. The Heme Oxygenase 1 Inducer (CoPP) Protects Human Cardiac Stem Cells Against Apoptosis Through Activation of The ERK/Nrf2 Signaling Pathway and Cytokine Release. J Biol Chem. 2012; 287(40): 33720-33732.
65. Hong KU, Li QH, Guo Y, et al. A highly sensitive and accurate method to quantify absolute numbers of c-kit+ cardiac stem cells following transplantation in mice. Basic Res Cardiol. 2013; 108(3): 346. doi: 10.1007/s00395-013-0346-0.
66. Hong KU, Guo Y, Li QH, et al. c-kit+ Cardiac stem cells alleviate post-myocardial infarction left ventricular dysfunction despite poor engraftment and negligible retention in the recipient heart. PloS one. 2014; 9: e96725 doi: 10.1371/journal.pone.0096725.
67. Brooks AC, Guo Y, Singh M, McCracken J, Xuan YT, Srivastava S, Bolli R, Bhatnagar A. Endoplasmic reticulum stress-dependent activation of ATF3 mediates the late phase of ischemic preconditioning. Journal of molecular and cellular cardiology. 2014; 76C: 138-147. doi: 10.1016/j.yjmcc.2014.08.011.